Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...
In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.
Bullish option flow detected in Novo Nordisk (NVO) with 21,940 calls trading, 1.5x expected, and implied vol increasing almost 3 points to ...
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
There are many opportunities available in the international markets that never make the news in the US. The VEA and VWO ETFs ...
A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...
19h
Zacks Small Cap Research on MSNRANI: Impressive Bioavailability for RT-116RANI READ THE FULL RANI RESEARCH REPORT On February 5th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
MarketBeat on MSN21h
These 3 Stocks Just Announced Major Dividend HikesThese three stocks just announced significant quarterly dividend increases that they are set to pay out soon. While they all ...
The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...
There's a boom in the use of weight loss medications with more new ones on their way, but they are recommended only for the clinically obese. A slew of new weight loss drugs are being tested in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results